Categories: HealthcareNews

Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference.

Nautilus’ management is scheduled to participate in a fireside chat on Monday, June 10, 2024, at 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

Staff

Recent Posts

Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025

Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV)…

2 hours ago

ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025

– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial…

2 hours ago